HR-2319-119
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 380.
Sponsored by Brendan Boyle (D-PA)
What it does
This bill would require the Department of Health and Human Services (HHS) to conduct an interagency review focused on accelerating lung cancer research, prevention, and awareness specifically for women and underserved populations. The review would assess existing research and identify knowledge gaps, find new opportunities for collaborative research on causes, prevention, screening, diagnosis, and treatment, and produce recommendations for a national lung cancer screening strategy and public education campaign.
Who benefits
Women with lung cancer or at risk of developing it, particularly those who have never smoked (a group disproportionately represented among women with lung cancer). Underserved and minority populations who face higher barriers to screening and diagnosis. Researchers and academic institutions that could receive new funding or collaboration opportunities identified by the review. Public health advocates focused on lung cancer awareness. Oncologists and pulmonologists who would benefit from clearer national screening guidelines. Patients who may gain earlier access to screening and diagnosis if recommendations are implemented.
Who is hurt
No group faces direct, immediate harm from this bill, as it is a study and review mandate rather than a regulatory or spending measure. Federal agency staff at HHS and relevant interagency partners would bear the administrative burden of conducting the review. Competing public health research priorities could receive relatively less attention or resources if agency bandwidth is redirected. Taxpayers would bear any costs associated with conducting the review, though those costs are not specified in the bill text.
Supporters argue
Supporters argue that lung cancer is the leading cause of cancer death among women, yet research and screening programs have historically been designed around male patient populations and smoking-related risk profiles, leaving women — especially never-smokers — underserved. They contend that a coordinated interagency review is a necessary first step to identify gaps and align federal resources, pointing to evidence that women are diagnosed at later stages and have different biological risk factors than men, making targeted research and screening strategies medically justified.
Opponents argue
Opponents argue that the bill creates a study mandate without guaranteed follow-through — Congress has no obligation to act on the review's recommendations, meaning the effort could produce a report that sits unused. They contend that existing agencies such as the National Cancer Institute already conduct lung cancer research and that adding a new interagency review layer duplicates ongoing work, consumes limited agency resources, and delays action that could be taken under current authority without new legislation.